bupivacaine has been researched along with Brain Ischemia in 7 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with tetracaine or bupivacaine significantly prolonged the latency of rapid depolarization." | 1.31 | Bupivacaine, but not tetracaine, protects against the in vitro ischemic insult of rat hippocampal CA1 neurons. ( Higashi, H; Kano, T; Niiyama, S; Tanaka, E; Yamamoto, S; Yasumoto, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ward, JM | 1 |
| Buslov, AM | 1 |
| Vallender, EJ | 1 |
| Li, X | 1 |
| Huo, X | 1 |
| Zhang, C | 1 |
| Ma, X | 1 |
| Han, F | 1 |
| Wang, G | 1 |
| Treggiari, MM | 1 |
| Romand, JA | 1 |
| Martin, JB | 1 |
| Reverdin, A | 1 |
| Rüfenacht, DA | 1 |
| de Tribolet, N | 1 |
| Lim, YJ | 1 |
| Huang, Y | 1 |
| Fang, H | 1 |
| Zuo, Z | 1 |
| Pick, MJ | 1 |
| Taylor, GW | 1 |
| Helms, U | 1 |
| Weihrauch, H | 1 |
| Jacobitz, K | 1 |
| Niiyama, S | 1 |
| Tanaka, E | 1 |
| Yamamoto, S | 1 |
| Yasumoto, S | 1 |
| Kano, T | 1 |
| Higashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cervical Sympathetic Block to Increase Cerebral Blood Flow in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT05230134] | 10 participants (Anticipated) | Interventional | 2023-07-27 | Enrolling by invitation | |||
| Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study[NCT05445921] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2022-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will be asked to complete the ODOR, which is a patient-reported outcome measure assessing physical problems, functional limitations, and emotional consequences of olfactory dysfunction.~The ODOR has a minimum score of 0 and a maximum score of 112 with higher scores indicating a greater degree of impairment and limitation. The minimal clinically important difference is a change of 15 points." (NCT05445921)
Timeframe: baseline, 5-10 days post SGB #1, and 1 month
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| ODOR at Baseline | ODOR at 1 Week | ODOR at 1 Month | |
| Stellate Ganglion Block | 62 | 57 | 50.5 |
"Participants will complete the 40-item scratch and sniff UPSIT and mean change will be assessed.~The UPSIT has a minimum score of 0 and maximum score of 40 with lower scores indicating a greater degree of impairment. An UPSIT score of >33 for men and >34 for women is considered normosmic, and the minimal clinically important difference is a change of 4 points." (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| UPSIT at Baseline | UPSIT at 1 Week | UPSIT at 1 Month | |
| Stellate Ganglion Block | 16.5 | 21 | 22.5 |
Participants will be asked about their change in olfactory dysfunction on a 7-point Likert scale from much better to much worse. (NCT05445921)
Timeframe: 5-10 days post SGB #1 and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-I for Smell Loss at 1 Week71922197 | CGI-I for Smell Loss at 1 Month71922197 | CGI-I for Smell Distortion at 1 Week71922197 | CGI-I for Smell Distortion at 1 Month71922197 | CGI-I for Taste Loss at 1 Week71922197 | CGI-I for Taste Loss at 1 Month71922197 | CGI-I for Taste Distortion at 1 Week71922197 | CGI-I for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||
| About the Same | Slightly Better | Much Better | Moderately Better | |||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 15 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 14 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 13 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||
Participants will be asked about the severity of their olfactory dysfunction (and gustatory dysfunction) on a 5-point Likert scale from no smell loss to severe smell loss. (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-S for Smell Loss at Baseline71922197 | CGI-S for Smell Loss at 1 Week71922197 | CGI-S for Smell Loss at 1 Month71922197 | CGI-S for Smell Distortion at Baseline71922197 | CGI-S for Smell Distortion at 1 Week71922197 | CGI-S for Smell Distortion at 1 Month71922197 | CGI-S for Taste Loss at Baseline71922197 | CGI-S for Taste Loss at 1 Week71922197 | CGI-S for Taste Loss at 1 Month71922197 | CGI-S for Taste Distortion at Baseline71922197 | CGI-S for Taste Distortion at 1 Week71922197 | CGI-S for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||||||||||||||||||||||||||
| No Problem | Very Mild Problem | Mild Problem | Moderate Problem | Severe Problem | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 trials available for bupivacaine and Brain Ischemia
| Article | Year |
|---|---|
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
[Cardio-circulatory changes following peridural anaesthesia with and without adrenaline-containing local anaesthetics in elderly patients (author's transl)].
Topics: Aged; Aging; Anesthesia, Epidural; Brain Ischemia; Bupivacaine; Coronary Disease; Epinephrine; Heart | 1980 |
5 other studies available for bupivacaine and Brain Ischemia
| Article | Year |
|---|---|
Twinning and survivorship of captive common marmosets (Callithrix jacchus) and cotton-top tamarins (Saguinus oedipus).
Topics: Animals; Animals, Laboratory; Brain Ischemia; Bupivacaine; Callithrix; Electroencephalography; Eutha | 2014 |
Role of continuous high thoracic epidural anesthesia in hippocampal apoptosis after global cerebral ischemia in rats.
Topics: Anesthesia, Epidural; Anesthetics, Local; Animals; Apoptosis; bcl-2-Associated X Protein; Brain Isch | 2014 |
Effects of local and intravenous anesthetics on the activity of glutamate transporter type 2.
Topics: Anesthetics, Intravenous; Anesthetics, Local; Animals; Brain Ischemia; Bupivacaine; Cell Membrane; E | 2003 |
Selective shunting on the basis of carotid clamping under regional anesthesia.
Topics: Blood Pressure; Brain Ischemia; Bupivacaine; Carotid Arteries; Carotid Artery Diseases; Catheterizat | 1984 |
Bupivacaine, but not tetracaine, protects against the in vitro ischemic insult of rat hippocampal CA1 neurons.
Topics: Anesthetics, Local; Animals; Brain Ischemia; Bupivacaine; Calcium; Cell Hypoxia; Dose-Response Relat | 2002 |